BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd. readouts ·
  AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sichuan Kelun-Biotech Biopharmace
 utical Co.\, Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06448312-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06448312)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Pembro
 lizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lun
 g Cancer\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06448312
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Chemot
 herapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1
  Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05631262-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT05631262)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 Monotherapy i
 n Selected Subjects With Advanced Solid Tumors\nEstimated primary completi
 on: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05631262
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05265091-2472@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05265091)
DESCRIPTION:Lunbotinib\, phase 1/2.\nStudy: A Study of KL590586 in Patients
  With Advanced Solid Tumors\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lunbotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05265091
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081959-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06081959)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of SKB264 for Locally Advanced\, Recurrent or Metas
 tatic HR+/HER2- Breast Cancer\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06081959
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05443126-2472@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05443126)
DESCRIPTION:Lunbotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Maligna
 ncies\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lunbotinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05443126
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279364-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06279364)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of SKB264 Versus Investigator's Choice Chemotherapy in Patients With U
 nresectable Recurrent or Metastatic Triple-Negative Breast Cancer\nEstimat
 ed primary completion: April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06279364
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670196-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06670196)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Osimertinib Versus Osimerti
 nib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations\, L
 ocally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06670196
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06074588-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06074588)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previous
 ly Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (
 NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)\nEst
 imated primary completion: 10 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06074588
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319730-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT05319730)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: A Study to Evaluat
 e Investigational Agents With or Without Pembrolizumab (MK-3475) in Partic
 ipants With Advanced Esophageal Cancer Previously Exposed to Programmed Ce
 ll Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatmen
 t (MK-3475-06B)\nEstimated primary completion: 11 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05319730
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308106-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SKB571: Phase 2 readout est. (NCT07308106)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07308106
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071337-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07071337)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SKB264 Versus Investigator's Choice of Chemoth
 erapy in Subjects With Unresectable Locally Advanced\, Relapsed\, or Metas
 tatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07071337
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312176)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single 
 Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of 
 Physician's Choice in Participants With HR+/HER2- Unresectable Locally Adv
 anced or Metastatic Breast Cancer (MK-2870-010)\nEstimated primary complet
 ion: 11 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06312176
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07329322)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase II Study of Sacituzumab Tirumotecan in Combination With Osi
 mertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal G
 rowth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer\nEstimated
  primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07329322
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564466-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SKB571: Phase 2 readout est. (NCT07564466)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Study of SKB571 in Participants Wit
 h Gastrointestinal Tumors\nEstimated primary completion: 31 August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07564466
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642780-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT05642780)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: SKB264 in Combinatio
 n With Pembrolizumab in Subjects With Selected Solid Tumors\nEstimated pri
 mary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05642780
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05294172-2581@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagitanlimab: Phase 3 readout est. (NCT05294172)
DESCRIPTION:Tagitanlimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: KL-A
 167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined 
 With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic
  Nasopharyngeal Carcinoma\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05294172
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646587-1536@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20271217
DTEND;VALUE=DATE:20271218
SUMMARY:WIN378: Phase 2 readout est. (NCT07646587)
DESCRIPTION:WIN378\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStud
 y: A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
 \nEstimated primary completion: 17 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/win378#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07646587
URL:https://assetmemo.bio/drug/win378#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854509-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07854509)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI F
 ailure\nEstimated primary completion: 30 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07854509
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341100-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07341100)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Study to Evaluate th
 e Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the P
 K of SKB264 in OC\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07341100
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132958-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06132958)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy
  Endometrial Cancer (MK-2870-005)\nEstimated primary completion: 10 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-t
 irumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06132958
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230405-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280119
DTEND;VALUE=DATE:20280120
SUMMARY:SKB571: Phase 2 readout est. (NCT07230405)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Phase II Study of SKB571 in Patient
 s With Lung Cancer\nEstimated primary completion: 19 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07230405
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizum
 ab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NS
 CLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (T
 PS) ≥ 50% (MK-2870-007)\nEstimated primary completion: 25 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6170788
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814066-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SKB571: Phase 2 readout est. (NCT07814066)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Multicenter\, Open-label\, Phase II
  Umbrella Study to Evaluate the Efficacy and Safety of the Investigational
  Product in Participants With Advanced or Metastatic Pancreatic Cancer\nEs
 timated primary completion: 28 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07814066
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483334-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06483334)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: A Study of Efficac
 y and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin 
 (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3
 475-04C/KEYMAKER-U04)\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0648333
 4
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324629-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07324629)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: Sacituzumab Tirumote
 can in Participants With Locally Advanced or Metastatic Thymic Carcinoma\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07324629
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445972-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06445972)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: Substudy 06D: Comb
 ination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-
 3475-06D/Keymaker-U06)\nEstimated primary completion: 9 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06445972
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06459180-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06459180)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Trea
 tment of Physician's Choice as Second-line Treatment for Participants With
  Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101
 /ENGOT-cx20)\nEstimated primary completion: 15 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06459180
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697586-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07697586)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07697586
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305754-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06305754)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplat
 in Combination Therapy in Participants With Epidermal Growth Factor (EGFR)
 -Mutated\, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Hav
 e Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06305754
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668154-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SKB571: Phase 2 readout est. (NCT07668154)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Phase II Study to Evaluate the Effi
 cacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07668154
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120503-1536@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:WIN378: Phase 2 readout est. (NCT07120503)
DESCRIPTION:WIN378\, phase 2\, Asthma.\nStudy: Study to Evaluate the Safety
 \, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe A
 sthma\nEstimated primary completion: 1 October 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/win378#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07120503
URL:https://assetmemo.bio/drug/win378#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SKB571: Phase 2 readout est. (NCT07622186)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Can
 cer (NSCLC)\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296809-2581@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07296809)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: SKB500 Combinations in Patients
  With Small Cell Lung Cancer\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07296809
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan
  (Sac-TMT\; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NS
 CLC) [MK-2870-023]\nEstimated primary completion: 12 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335497-10868@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:CR-001: Phase 1/2 readout est. (NCT07335497)
DESCRIPTION:CR-001\, phase 1/2\, Solid Tumors.\nStudy: CR-001 in Adult Part
 icipants With Locally Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: February 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cr-001#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07335497
URL:https://assetmemo.bio/drug/cr-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876128-2066@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:SKB571: Phase 1/2 readout est. (NCT07876128)
DESCRIPTION:SKB571\, phase 1/2.\nStudy: A Clinical Trial of MK-2750 in Part
 icipants With Advanced Solid Tumors (MK-2750-002)\nEstimated primary compl
 etion: 12 April 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /skb571#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07876128
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824467-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06824467)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-28
 70) Maintenance Treatment Versus Standard of Care in Participants With Pla
 tinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov
 84/GOG-3103)\nEstimated primary completion: 27 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06824467
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07419295-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290727
DTEND;VALUE=DATE:20290728
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07419295)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) to Treat Urot
 helial Cancer (MK-2870-031)\nEstimated primary completion: 27 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 419295
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small
  Cell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07286149
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: Substudy 06C: A St
 udy of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherap
 y in Participants With First-Line Locally Advanced Unresectable/Metastatic
  Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated pri
 mary completion: 12 September 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06469944
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428409-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06428409)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: A Clinical Study o
 f MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers
  (MK-9999-02A)\nEstimated primary completion: 16 October 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06428409
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 
 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat S
 arcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-
 U01J)\nEstimated primary completion: 15 November 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586943-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07586943)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: SKB118 Injection i
 n Advanced Solid Tumors\nEstimated primary completion: December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07586
 943
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841354-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20300518
DTEND;VALUE=DATE:20300519
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06841354)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) as Monotherapy and in C
 ombination With Pembrolizumab (MK-3475) in Participants With Triple-Negati
 ve Breast Cancer (MK-2870-011/TroFuse-011)\nEstimated primary completion: 
 18 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06841354
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393374-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06393374)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: Saci
 tuzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Di
 d Not Achieve pCR (MK-2870-012)\nEstimated primary completion: 16 December
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-ti
 rumotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06393374
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785609-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07785609)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2.\nStudy: A Clinical Trial of 
 MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid 
 Tumors (MK-2010)\nEstimated primary completion: 30 September 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07785609
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pe
 mbrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
 er (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary comple
 tion: 29 October 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07216703
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07829783)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Bladder Cancer.\nStudy: A C
 linical Trial of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) and Pembroliz
 umab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)\nEstimat
 ed primary completion: 17 November 2031. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07829783
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780111-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20320104
DTEND;VALUE=DATE:20320105
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT06780111)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: Substudy 06E: Umbr
 ella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYM
 AKER-U06)\nEstimated primary completion: 4 January 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06780111
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable
  Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated 
 primary completion: 6 February 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952504-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20320524
DTEND;VALUE=DATE:20320525
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06952504)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Endometrial Cancer.\nStudy:
  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With 
 Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Partici
 pants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroF
 use-033/GOG-3119/ENGOT-en29)\nEstimated primary completion: 24 May 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumoteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 952504
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908524-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20320629
DTEND;VALUE=DATE:20320630
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07908524)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2.\nStudy: MK-2870-U01 Substu
 dy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer
  (MK-2870-01A)\nEstimated primary completion: 29 June 2032. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07908524
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318558-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20330225
DTEND;VALUE=DATE:20330226
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07318558)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Ovarian Cancer.\nStudy: A C
 linical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian 
 Cancer (MK-2870-021)\nEstimated primary completion: 25 February 2033. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318
 558
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Breast Cancer.\nStudy: A Cl
 inical Study of Sacituzumab Tirumotecan (Sac-TMT\, MK-2870) in People With
  Breast Cancer (MK-2870-032)\nEstimated primary completion: 23 March 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumote
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06966700
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312137-1991@assetmemo.bio
DTSTAMP:20261121T010451Z
DTSTART;VALUE=DATE:20340221
DTEND;VALUE=DATE:20340222
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312137)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study to Assess Efficacy and Safety of Pembrolizumab With or Wi
 thout Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resect
 able Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complet
 e Response (pCR) (MK-2870-019)\nEstimated primary completion: 21 February 
 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06312137
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
